Vical Incorporated (VICL)
(Delayed Data from NSDQ)
$1.16 USD
-0.01 (-0.85%)
Updated May 3, 2019 03:57 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Fresh Tracks Therapeutics, Inc. [VICL]
Reports for Purchase
Showing records 1 - 20 ( 117 total )
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The company is dropping coverage of the following stocks
Provider: IFS Securities, Inc.
Analyst: Research Department
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Reports 2Q19; Shareholder Vote and Merger Closure Ahead
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Vical Enters Into Merger Agreement with Brickell Biotech
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Outlook Uncertain Following VL-2397 Program Discontinuation; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Vical Scales Back Operations While Looking for a Buyer
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Update on Vical: Enrollment in VL-2397 Pivotal Trial Appears On-Track
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Financial Results Reported; Substantial Spending Drop; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Reports Better Than Expected Financial Results for 3Q2018
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for VICL
Provider: ValuEngine, Inc
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage of VICL shares to reallocate our research resources.
Provider: Roth Capital Partners, Inc.
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Highlights of Vical Presentation at Investor Conference
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Financial Results Reported; Awaiting Results of Strategic Options Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
VCL-HB-01 Failure Leaves VL-2397 a Standalone Asset; Reiterate Buy and Lowering Target to $3.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HSV-2 Vaccine Phase II does not meet endpoints; Re-evaluating VICL based on VL-2397
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q 2018 Results Reported; HCL-HB-01 Phase 2 Data Next Month; Cash Runway Solid; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fresh Tracks Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q and FY2017 Financials Reported; Near-Term Catalysts Ahead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R